Company news
Protagonist Therapeutics, Inc. news in 2025
Protagonist Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 5, 2025
DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 26, 2025
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 2, 2025
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 26, 2025
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
October 6, 2025
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 17, 2025
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 16, 2025
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
September 14, 2025
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
September 10, 2025
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
August 25, 2025
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 24, 2025
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 5, 2025
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
July 20, 2025
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 29, 2025
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 25, 2025
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
May 31, 2025
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 20, 2025
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 8, 2025
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 5, 2025
Protagonist Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
May 5, 2025
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Protagonist Therapeutics Reports Granting of Inducement Award
April 15, 2025
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 17, 2025
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 9, 2025
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 8, 2025
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 2, 2025
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 20, 2025
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 28, 2025
Protagonist Therapeutics Reports Granting of Inducement Awards
January 5, 2025
Decks in 2025
- Technical Presentation (March 2025)
Technical · 13 slides · Mar 3, 2025
- Technical Presentation (February 2025)
Technical · 57 slides · Feb 6, 2025